Please assess the completion status of the following clinical trial:

Trial Title: Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Localized (N0, M0) disease~ * No small cell or transitional cell carcinoma in the biopsy specimen~* Considered to be at high risk for recurrence based on the presence of at least one of the following adverse prognostic features:~  * T stage ≥ 3a~ * Gleason score ≥ 8~ * Baseline prostate-specific antigen (PSA) \> 20 ng/mL~* Deemed to be an appropriate candidate for chemotherapy, as assessed by a medical oncologist~* Negative pelvic and para-aortic lymph nodes on CT scan or MRI of the abdomen and pelvis~  * Any lymph node appearing ≥ 1.5 cm on CT scan or MRI must be histologically negative by either needle aspirate or lymph node dissection~* No metastases by chest x-ray and bone scan~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10.0 g/dL~* AST and/or ALT ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Total bilirubin normal~* Serum creatinine ≤ 1.5 times ULN~* Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French~* Fertile patients must use effective contraception~* No history of other malignancies, except adequately treated nonmelanoma skin cancer or other curatively treated solid tumor with no evidence of disease for \> 5 years~* No serious non-malignant disease resulting in a life expectancy of \< 10 years~* No known hypersensitivity to any study medications~* No existing peripheral neuropathy ≥ grade 2~* No bilateral hip replacement prostheses~* No contraindication to pelvic radiotherapy including, but not limited to, inflammatory bowel disease or severe bladder irritability~* No medical condition that would contraindicate the study treatment regimen, including severe respiratory insufficiency, uncontrolled diabetes, or severe hypertension~* No other serious illness or psychiatric or medical condition that would preclude management of the patient according to the study, including active uncontrolled infection or significant cardiac dysfunction~PRIOR CONCURRENT THERAPY:~* Prior androgen suppression therapy allowed provided it was initiated no more than 4 weeks prior to study entry~* At least 4 weeks since prior 5-alpha-reductase inhibitors (e.g., finasteride) for benign prostatic hypertrophy~* No prior cytotoxic anticancer therapy~* No prior chemotherapy for carcinoma of the prostate~* No prior surgical treatment for carcinoma of the prostate, except transurethral resection or bilateral orchiectomy~* No prior pelvic radiotherapy~* No concurrent nilutamide~* No other concurrent investigational drugs~* No other concurrent anticancer therapy (cytotoxic therapy, biologic/immunotherapy, or radiotherapy)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antiandrogen; LHRH; Docetaxel, Radiation Therapy (Type: ACTIVE_COMPARATOR): Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
- Antiandrogen; LHRH; Radiation Therapy (Type: ACTIVE_COMPARATOR): Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)

Based on this trial design, predict the completion outcome and termination type (if applicable).